Which tumor marker is most commonly elevated in pancreatic adenocarcinoma and is used for monitoring treatment response?

Explanation

## Tumor Markers in Pancreatic Cancer **Key Point:** CA 19-9 is the most clinically useful tumor marker for pancreatic adenocarcinoma, used for diagnosis support, prognosis assessment, and monitoring treatment response. ### CA 19-9: Clinical Utility and Characteristics **High-Yield:** CA 19-9 (carbohydrate antigen 19-9): - Elevated in 80–85% of patients with pancreatic adenocarcinoma - Elevated in only 50% of early-stage disease (limited sensitivity for screening) - Not specific to pancreatic cancer (also elevated in benign conditions: pancreatitis, cirrhosis, cholecystitis) - Baseline level correlates with tumor burden and prognosis - Useful for monitoring response to chemotherapy and detecting recurrence - Levels >1000 U/mL suggest advanced/metastatic disease ### Comparison of Tumor Markers in GI Malignancies | Marker | Primary Use | Sensitivity in PDAC | Specificity | Notes | | --- | --- | --- | --- | --- | | CA 19-9 | Pancreatic cancer | 80–85% | Low (benign conditions elevate it) | Best for monitoring, not screening | | CEA | Colorectal, gastric cancer | 30–40% in PDAC | Low | Not useful for pancreatic cancer | | AFP | Hepatocellular carcinoma | Rare elevation | High | Not relevant for PDAC | | PSA | Prostate cancer | Not elevated | High | No role in pancreatic cancer | ### Clinical Applications of CA 19-9 in PDAC **Clinical Pearl:** A rising CA 19-9 during chemotherapy (despite radiological stability) may indicate treatment failure and warrant early change of regimen. Conversely, a falling CA 19-9 correlates with treatment response. **Mnemonic: "CA 19-9 for Pancreatic Monitoring — Baseline, Response, Recurrence"** — Use CA 19-9 at baseline for prognosis, during treatment for response assessment, and post-treatment for surveillance. ### Limitations of CA 19-9 1. **Not suitable for screening:** Low sensitivity in early-stage disease; high false-positive rate in benign conditions 2. **Lewis antigen negativity:** ~10% of population lacks the Lewis antigen and cannot produce CA 19-9 (false negatives) 3. **Non-specific elevation:** Pancreatitis, cholecystitis, and other GI malignancies can elevate CA 19-9 **Warning:** Do NOT use CA 19-9 alone for diagnosis — always correlate with imaging and clinical presentation. [cite:Harrison 21e Ch 297]